|
||||
|
Product trade name: CN-25
Pharmaceutical active ingredients containing related brand and generic drugs, medications or other health care products: CN-25 available forms, composition, doses: CN-25 destination | category: Indications and usages, anatomical therapeutic chemical and diseases classification codes: Pharmaceutical companies, researchers, developers, manufacturers, distributors and suppliers: Online pharmacy, drugstores, pharma, health and beauty shops selling this or related pharmaceutical products: There is an additional general information about this medication active ingredient cinnarizine: Pharmacological action CN-25 Masa Lab is a calcium channel blocker class IV with a predominant effect on the brain vessels, a derivative of piperazine. This medication improves cerebral, coronary and peripheral circulation. CN-25 Masa Lab violates the entrance of calcium ions into vascular smooth muscle cells. This drug lowers the tone of arteriolar smooth muscle, decreases the vasoconstrictor response to biogenic substances (epinephrine, norepinephrine, bradykinin). Cinnarizine reduces the excitability of the vestibular apparatus. In patients with impaired peripheral circulation CN-25 Masa Lab improves blood flow and potentiates postischemic hyperemia. This medicine increases the resistance of tissue to hypoxia. Pharmacokinetics After oral administration CN-25 Masa Lab is absorbed from the gastrointestinal tract, Cmax in plasma is reached after 1-4 h. The plasma protein binding is 91%. This medication is metabolized. T1/2 is 3-6 hours. CN-25 Masa Lab is eliminated through the intestine largely unchanged, with the urine - mainly in the form of metabolites. Why is CN-25 Masa Lab prescribed? Ischemic attacks (including the residual effects after a stroke). Labyrinth disorders (including for maintenance therapy for dizziness, tinnitus, nystagmus, nausea and vomiting of labyrinth origin). Motion sickness (as a prophylactic agent). Prophylaxis of migraine. Meniere's disease. Prevention and treatment of disorders of peripheral circulation - atherosclerosis, thromboangiitis obliterans, Raynaud's disease, diabetic angiopathy, acrocyanosis. Dosage and administration The dosage regimen is individual. CN-25 Masa Lab is taken orally in 25-50-75 mg 3 times / day after a meal. If necessary, the treatment can begin with half the dose and gradually increasing. To achieve the optimal therapeutic effect is used continuously for several months. CN-25 Masa Lab side effects, adverse reactions Digestive system: dyspepsia, dry mouth, rarely - cholestatic jaundice. CNS: headache, drowsiness; in elderly patients in long-term use may be extrapyramidal symptoms, depression. Allergic reactions: rarely - skin rash. Other: weight gain, increased sweating, in rare cases - lupus-like syndrome, lichen planus. CN-25 Masa Lab contraindications Hypersensitivity to cinnarizine. Using during pregnancy and breastfeeding During pregnancy and lactation (breastfeeding) CN-25 Masa Lab usage is possible only in exceptional cases, when the expected benefit to the mother far outweighs the potential risk to the fetus or infant. Special instructions Use CN-25 Masa Lab with caution in patients with hypertension. With prolonged use is recommended to perform control examination of liver, kidney, peripheral blood picture. At the beginning of treatment you should refrain from potentially hazardous activities that require attention and speed of psychomotor reactions. CN-25 Masa Lab drug interactions When this drug applied simultaneously with: - tricyclic antidepressants, hypnotics, drugs that have a sedative effect, alcohol, ethanol-containing medication increases the effects on the CNS. - antihypertensive drugs increased hypotensive effect. - nootropics, vasodilators - increases the action of nootropic drugs and vasodilators. - phenylpropanolamine reduces sedation effect of CN-25 Masa Lab. CN-25 Masa Lab in case of emergency / overdose Treatment: gastric lavage, taking activated charcoal, symptomatic therapy. There is no a specific antidote.
Comments
|
|
|||
|
||||